EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Resonance Health's enterprise value is A$28.83 Mil.
Resonance Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$5.57 Mil. Therefore, Resonance Health's EV-to-Revenue for today is 5.18.
The historical rank and industry rank for Resonance Health's EV-to-Revenue or its related term are showing as below:
ASX:RHT'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.58 Med: 5.45 Max: 29.38
Current: 5.18
During the past 13 years, the highest EV-to-Revenue of Resonance Health was 29.38. The lowest was 1.58. And the median was 5.45.
ASX:RHT's EV-to-Revenue is ranked worse than 78.85% of 662
companies
in the Healthcare Providers & Services industry
Industry Median: 1.89
vs ASX:RHT: 5.18
As of today (2024-05-12), Resonance Health's stock price is A$0.077.
Resonance Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.01. Therefore, Resonance Health's PS Ratio for today is 5.92.
Resonance Health EV-to-Revenue Historical Data
The historical data trend for Resonance Health's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Resonance Health's EV-to-Revenue
For the Health Information Services subindustry, Resonance Health's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health's EV-to-Revenue Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Resonance Health's EV-to-Revenue falls into.
Resonance Health's current Enterprise Value is A$28.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$5.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) EV-to-Revenue Explanation
Resonance Health's share price for today is A$0.077.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Resonance Health's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:RHT has been successfully added to your 